{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:37:48Z","timestamp":1792337868123,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH 5342"],"award-info":[{"award-number":["OPPGH 5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Improved drug regimens are needed to accelerate elimination of lymphatic filariasis in Africa. This study determined whether a single co-administered dose of ivermectin plus diethylcarbamazine plus albendazole [IDA] is noninferior to standard 3 annual doses of ivermectin plus albendazole (IA) used in many LF-endemic areas of Africa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Treatment-naive adults with Wuchereria bancrofti microfilaremia in C\u00f4te d\u2019Ivoire were randomized to receive a single dose of IDA (n = 43) or 3 annual doses of IA (n = 52) in an open-label, single-blinded trial. The primary endpoint was the proportion of participants who were microfilaria (Mf) negative at 36 months. Secondary endpoints were Mf clearance at 6, 12, and 24 months; inactivation of adult worm nests; and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At 36 months posttreatment with IDA, 18\/33 (55%; 95% CI, 38\u201372%) cleared Mf versus 33\/42 (79%; 67\u201391%) with IA (P = .045). At 6 and 12 months IDA was superior to IA in clearing Mf (89% [77\u201399%] and 71% [56\u201385%]), respectively, versus 34% (20\u201348%) and 26% (14\u201342%) (P &amp;lt; .001). IDA was equivalent to IA at 24 months (61% [45\u201377%] vs 54% [38\u201372%]; P = .53). IDA was superior to IA for inactivating adult worms at all time points. Both treatments were well tolerated, and there were no serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A single dose of IDA was superior to 2 doses of IA in reducing the overall Mf burden by 24 months. Reinfection may have contributed to the lack of sustained clearance of Mf with IDA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02974049.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1050","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T19:20:02Z","timestamp":1571685602000},"page":"e68-e75","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in C\u00f4te d\u2019Ivoire: An Open-label Randomized Controlled Trial"],"prefix":"10.1093","volume":"71","author":[{"given":"Catherine M","family":"Bjerum","sequence":"first","affiliation":[{"name":"Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allassane F","family":"Ouattara","sequence":"additional","affiliation":[{"name":"Centre Suisse de Recherche Scientifique en C\u00f4te d\u2019Ivoire, Abidjan, C\u00f4te d\u2019Ivoire"},{"name":"Universit\u00e9 Nangui Abrogoua, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9it\u00e9","family":"Aboulaye","sequence":"additional","affiliation":[{"name":"Programme National de la Lutte Contre la Schistosomiase, Les Geohelminthiases et la Filariose Lymphatique, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Kouadio","sequence":"additional","affiliation":[{"name":"Centre Suisse de Recherche Scientifique en C\u00f4te d\u2019Ivoire, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanga K","family":"Marius","sequence":"additional","affiliation":[{"name":"Universite Alassane Ouattara Centre Hospitalier Universitaire de Bouake, Bouak\u00e9, C\u00f4te d\u2019Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt J","family":"Andersen","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J","family":"Weil","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin G","family":"Koudou","sequence":"additional","affiliation":[{"name":"Centre Suisse de Recherche Scientifique en C\u00f4te d\u2019Ivoire, Abidjan, C\u00f4te d\u2019Ivoire"},{"name":"Universit\u00e9 Nangui Abrogoua, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-7860","authenticated-orcid":false,"given":"Christopher L","family":"King","sequence":"additional","affiliation":[{"name":"Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Veterans Affairs Research Service, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"2020102308120901200_CIT0001","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1371\/journal.pntd.0000317","article-title":"The global programme to eliminate lymphatic filariasis: health impact after 8 years","volume":"2","author":"Ottesen","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"2020102308120901200_CIT0002","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0065-308X(07)65003-9","article-title":"Epidemiological modelling for monitoring and evaluation of lymphatic filariasis control","volume":"65","author":"Michael","year":"2007","journal-title":"Adv Parasitol"},{"key":"2020102308120901200_CIT0003","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"King","year":"2018","journal-title":"N Engl J Med"},{"key":"2020102308120901200_CIT0004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020102308120901200_CIT0005","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study","volume":"16","author":"Weil","year":"2019","journal-title":"PLoS Med"},{"key":"2020102308120901200_CIT0006","volume-title":"Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis","author":"World Health Organization","year":"2017"},{"key":"2020102308120901200_CIT0007","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4269\/ajtmh.15-0916","article-title":"Measurement of circulating filarial antigen levels in human blood with a point-of-care test strip and a portable spectrodensitometer","volume":"94","author":"Chesnais","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2020102308120901200_CIT0008","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4269\/ajtmh.13-0245","article-title":"Semi-quantitative scoring of an immunochromatographic test for circulating filarial antigen","volume":"89","author":"Chesnais","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020102308120901200_CIT0009","first-page":"83","article-title":"Periodicity of Wuchereria bancrofti var. Pacifica filariasis in French Polynesia","volume":"44","author":"Moulia-Pelat","year":"1993","journal-title":"Trop Med Parasitol"},{"key":"2020102308120901200_CIT0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4269\/ajtmh.13-0089","article-title":"Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood","volume":"89","author":"Weil","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020102308120901200_CIT0011","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0035-9203(96)90437-X","article-title":"Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazine","volume":"90","author":"Ismail","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-3156.1996.d01-79.x","article-title":"Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis","volume":"1","author":"Dreyer","year":"1996","journal-title":"Trop Med Int Health"},{"key":"2020102308120901200_CIT0013","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0035-9203(00)90135-4","article-title":"Single-dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment","volume":"94","author":"Dunyo","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0035-9203(00)90278-5","article-title":"A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana","volume":"94","author":"Dunyo","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0035-9203(01)90257-3","article-title":"Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis","volume":"95","author":"Ismail","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0035-9203(98)90972-5","article-title":"Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis","volume":"92","author":"Ismail","year":"1998","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0017","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.trstmh.2003.12.005","article-title":"The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania","volume":"98","author":"Simonsen","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0018","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1086\/657063","article-title":"Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels","volume":"51","author":"Dembele","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020102308120901200_CIT0019","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(17)30175-5","article-title":"Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo","volume":"17","author":"Pion","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020102308120901200_CIT0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0035-9203(97)90405-3","article-title":"Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo","volume":"91","author":"Nor\u00f5es","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1179\/136485907X176517","article-title":"Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole","volume":"101","author":"Rizzo","year":"2007","journal-title":"Ann Trop Med Parasitol"},{"key":"2020102308120901200_CIT0022","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.trstmh.2005.05.006","article-title":"Does longevity of adult Wuchereria bancrofti increase with decreasing intensity of parasite transmission? Insights from clinical observations","volume":"99","author":"Dreyer","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020102308120901200_CIT0023","doi-asserted-by":"crossref","first-page":"e0007325","DOI":"10.1371\/journal.pntd.0007325","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in C\u00f4te d\u2019Ivoire","volume":"13","author":"Edi","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2020102308120901200_CIT0024","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/cid\/ciy003","article-title":"Are alternative strategies required to accelerate the global elimination of lymphatic filariasis? Insights from mathematical models","volume":"66","author":"Stolk","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020102308120901200_CIT0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"Irvine","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/7\/e68\/33994272\/ciz1050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/7\/e68\/33994272\/ciz1050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T12:14:37Z","timestamp":1603455277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/7\/e68\/5602915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,10,23]]},"published-print":{"date-parts":[[2020,10,23]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1050","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2019,10,23]]}}}